In line with this, there is great potential for enhancing risk classification, directing treatment choices, and developing tailored therapeutics for PCa by incorporating TMPRSS2:ERG fusion status and PTEN expression into clinical practice (130, 131). Here, TMPRSS2 is linked to posterior cortical atrophy.